1FG Stock Overview A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
FibroGen, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for FibroGen Historical stock prices Current Share Price US$0.38 52 Week High US$2.50 52 Week Low US$0.21 Beta 0.82 1 Month Change 5.42% 3 Month Change 48.52% 1 Year Change -39.95% 3 Year Change -97.18% 5 Year Change -99.06% Change since IPO -97.97%
Recent News & Updates
FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer Dec 16
Third quarter 2024 earnings released: US$0.17 loss per share (vs US$0.65 loss in 3Q 2023) Nov 14
FibroGen, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
FibroGen Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement Sep 17
New minor risk - Shareholder dilution Aug 09
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.90 loss in 2Q 2023) Aug 07 See more updates
FibroGen, Inc. Appoints David DeLucia as Chief Financial Officer Dec 16
Third quarter 2024 earnings released: US$0.17 loss per share (vs US$0.65 loss in 3Q 2023) Nov 14
FibroGen, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
FibroGen Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement Sep 17
New minor risk - Shareholder dilution Aug 09
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.90 loss in 2Q 2023) Aug 07
FibroGen, Inc. Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies Aug 01
FibroGen, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Index Jul 03
FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors Jun 05
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting May 24
First quarter 2024 earnings released: US$0.33 loss per share (vs US$0.81 loss in 1Q 2023) May 07
FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024 May 01 FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting
Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc Apr 17
Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer Apr 03
CEO & Director recently bought €87k worth of stock Mar 13
FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer Mar 11
Full year 2023 earnings released: US$2.92 loss per share (vs US$3.14 loss in FY 2022) Feb 27
FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024 Feb 21
New major risk - Financial position Feb 03
FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer Jan 25
Now 37% undervalued after recent price drop Nov 10
New minor risk - Financial position Nov 07
Third quarter 2023 earnings released: US$0.65 loss per share (vs US$0.98 loss in 3Q 2022) Nov 07
FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price Oct 29
FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price Oct 28
FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 24 FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer
Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023 Sep 08
Insufficient new directors Sep 01
Insufficient new directors Sep 01
Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy Aug 31
Second quarter 2023 earnings released: US$0.90 loss per share (vs US$0.78 loss in 2Q 2022) Aug 08
Fibrogen, Inc. Announces Chief Executive Officer Changes Jul 26
FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
New major risk - Share price stability Jun 27
Now 83% undervalued after recent price drop Jun 27
FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy Jun 08
FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia May 19
First quarter 2023 earnings released: US$0.81 loss per share (vs US$0.68 loss in 1Q 2022) May 09
Insider recently sold €113k worth of stock Apr 08
Executive VP & Chief Medical Officer recently sold €338k worth of stock Mar 12
Full year 2022 earnings released: US$3.14 loss per share (vs US$3.14 loss in FY 2021) Mar 01
FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 18
Third quarter 2022 earnings released: US$0.98 loss per share (vs US$0.54 profit in 3Q 2021) Nov 09
FibroGen, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 25
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes Aug 28
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes Aug 27
Second quarter 2022 earnings released: US$0.78 loss per share (vs US$1.45 loss in 2Q 2021) Aug 09
FibroGen, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
Fibrogen Announces Completion of Patient Enrollment in LELANTOS-2, A Phase 3 Clinical Study of pamrevlumab in Duchenne Muscular Dystrophy Jun 09
First quarter 2022 earnings released: US$0.68 loss per share (vs US$0.78 loss in 1Q 2021) May 11
FibroGen, Inc., Annual General Meeting, Jun 16, 2022 May 02
FibroGen, Inc. to Report Q1, 2022 Results on May 09, 2022 Apr 26
FibroGen, Inc. Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis Apr 21
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 02
FibroGen, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 15
Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.36 in 3Q 2020) Nov 10
Independent Director recently sold €128k worth of stock Sep 20
FibroGen, Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia Aug 26
Astellas Receives EC Approval for First-Inclass Evrenzo (Roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Aug 20
Second quarter 2021 earnings released: US$1.45 loss per share (vs US$0.95 loss in 2Q 2020) Aug 10
FibroGen, Inc. Announces Outcome of FDA Advisory Committee Review of Roxadustat Jul 16
Independent Director Kalevi Kurkijärvi has left the company Jul 13
Astellas Receives Positive CHMP Opinion for Evrenzo™ (Roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease Jun 26
Scott+Scott Attorneys At Law LLP Reminds Investors of Securities Class Action Against Fibrogen, Inc May 26
Forecast to breakeven in 2025 May 22
First quarter 2021 earnings released: US$0.78 loss per share (vs US$0.89 loss in 1Q 2020) May 12
The Schall Law Firm and Roche Freedman LLP Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc May 11
Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Fibrogen, Inc May 07
Rosen Law Firm Announces the Filing of a Class Action Lawsuit on Behalf of Purchasers of the Securities of FibroGen, Inc Apr 15
FibroGen, Inc. Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy Mar 17
Executive Advisor to Chief Executive Officer K. Yu has left the company Mar 17
Full year 2020 earnings released: US$2.11 loss per share (vs US$0.89 loss in FY 2019) Mar 02
Revenue misses expectations Mar 02
FibroGen, Inc. to Report Q4, 2020 Results on Mar 01, 2021 Feb 19
New 90-day high: €44.20 Feb 12
FibroGen, Inc. Enters into Supply Agreement with Astellas Pharma Europe Ltd Jan 29
New 90-day high: €39.00 Jan 26
New 90-day low: €31.66 Dec 30 FibroGen, Inc. Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2
FibroGen, Inc. Provides Regulatory Update on Roxadustat Dec 20
Fibrogen, Inc. Announces Appointment of Mark Eisner as Incoming Chief Medical Officer Dec 02
Astellas and FibroGen Receive Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis Nov 27
Revenue misses expectations Nov 08
Third quarter 2020 earnings released: EPS US$0.36 Nov 08
FibroGen, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 30
New 90-day low: €32.80 Oct 29
New 90-day high: €41.50 Oct 12
First half earnings released Aug 07
FibroGen, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Jul 24
New 90-day high - €39.09 Jul 16 Shareholder Returns 1FG DE Biotechs DE Market 7D 23.4% -2.6% -2.0% 1Y -40.0% -13.2% 6.8%
See full shareholder returns
Return vs Market: 1FG underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 1FG's price volatile compared to industry and market? 1FG volatility 1FG Average Weekly Movement 23.2% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 1FG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1FG's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
Show more FibroGen, Inc. Fundamentals Summary How do FibroGen's earnings and revenue compare to its market cap? 1FG fundamental statistics Market cap €38.73m Earnings (TTM ) -€117.03m Revenue (TTM ) €172.98m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1FG income statement (TTM ) Revenue US$180.02m Cost of Revenue US$195.17m Gross Profit -US$15.16m Other Expenses US$106.64m Earnings -US$121.79m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.21 Gross Margin -8.42% Net Profit Margin -67.66% Debt/Equity Ratio -45.1%
How did 1FG perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 13:30 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources FibroGen, Inc. is covered by 16 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Matthew Gerberry BofA Global Research Kennen MacKay Credit Suisse Paul Choi Goldman Sachs
Show 13 more analysts 
